Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

9.430 -1.160 (-10.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 904,565
Open 10.49
Bid (Size) 9.600 (1)
Ask (Size) 9.790 (20)
Prev. Close 10.59
Today's Range 9.410 - 10.49
52wk Range 9.410 - 45.00
Shares Outstanding 26,562,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock
Via Benzinga
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire

Performance

YTD
-44.8%
-44.8%
1 Month
-39.9%
-39.9%
3 Month
-43.1%
-43.1%
6 Month
-59.4%
-59.4%
1 Year
-71.5%
-71.5%

More News

Read More
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For March 6, 2025
Via Benzinga
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Unveiling 3 Analyst Insights On Arcturus Therapeutics
Via Benzinga
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
From Meiji Seika Pharma Co., Ltd. and ARCALIS, Inc.
Via Business Wire
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Via Benzinga
Exposures COVID-19
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
From Arcturus Therapeutics
Via Business Wire

Frequently Asked Questions

Is Arcturus Therapeutics Holdings Inc publicly traded?
Yes, Arcturus Therapeutics Holdings Inc is publicly traded.
What exchange does Arcturus Therapeutics Holdings Inc trade on?
Arcturus Therapeutics Holdings Inc trades on the Nasdaq Stock Market
What is the ticker symbol for Arcturus Therapeutics Holdings Inc?
The ticker symbol for Arcturus Therapeutics Holdings Inc is ARCT on the Nasdaq Stock Market
What is the current price of Arcturus Therapeutics Holdings Inc?
The current price of Arcturus Therapeutics Holdings Inc is 9.430
When was Arcturus Therapeutics Holdings Inc last traded?
The last trade of Arcturus Therapeutics Holdings Inc was at 04/01/25 04:00 PM ET
What is the market capitalization of Arcturus Therapeutics Holdings Inc?
The market capitalization of Arcturus Therapeutics Holdings Inc is 250.49M
How many shares of Arcturus Therapeutics Holdings Inc are outstanding?
Arcturus Therapeutics Holdings Inc has 250M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.